Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

OXFORD, England & BRISBANE, Australia--(BUSINESS WIRE)--Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore ...

(Nanowerk News) Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and ...

Nucleic acids are emerging as a third generation of pharmaceuticals following the clinical accomplishments of small-molecule drugs and biologics like proteins and monoclonal antibody (mAb) therapies.

A well-earned spotlight shines on mRNA vaccines, with recent Nobel prize accolades awarded to Katalin Karikó and Drew Weissman for their foundational research that enabled rapid and effective vaccine ...

In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.

This is the second article in Microbiologics’ series on Optimal QC in the Clinical Laboratory. In a previous article, we highlighted the importance of external quality control products for QC in the ...

Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project HER2 status was evaluated using ...

Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read sequencing, today announced the addition of three Oxford ...